Nitric oxide metabolite determinations reveal continuous inflammation in multiple sclerosis

Journal of Neuroimmunology

Volumn 136, Issue 1-2, 2003, Pages 112-118

  Danilov, Alexandre I ^a   Andersson, Magnus ^a   Bavand, Nasrin ^a   Wiklund, N Peter ^a   Olsson, Tomas ^a   Brundin, Lou ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Capillary electrophoresis; Inflammation; Multiple sclerosis; Nitric oxide

Indexed keywords

NITRIC OXIDE; NITRITE;

ADULT; AGED; ARTICLE; BRAIN INFECTION; CEREBROSPINAL FLUID; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OXIDATION; PRIORITY JOURNAL;

EID: 0037334950     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(02)00464-2     Document Type: Article

References (54)

1. Amber I.J., Hibbs J.B. Jr., Taintor R.R., Vavrin Z. The L-arginine dependent effector mechanism is induced in murine adenocarcinoma cells by culture supernatant from cytotoxic activated macrophages. J. Leukoc. Biol. 43(2):1988;187-192.
2. Andersson K.E. Neurotransmitters and neuroreceptors in the lower urinary tract. Curr. Opin. Obstetr. Gynecol. 8(5):1996;361-365. (Oct.).
3. Bagasra O., Michaels F.H., Zheng Y.M., Bobrovski L., Spitsin S.V., Fu Z.F., Tawardos R., Koprovski H. Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 92:1995;12041-12045.
4. Barnes P.J., Liew F.Y. Nitric oxide and asthmatic inflammation. Immunol. Today. 16:1995;128-130.
5. Bö L., Dawson T.M., Wesselingh S., Mörk S., Kong P.A., Hanley D., Trapp B.D. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann. Neurol. 36:1994;778-786.
6. Brosnan C.F., Battistini L., Raine C.S., Dickson D.W., Casadevall A., Lee S.C. Reactive nitrogen Intermediates in human neuropathology: an overview. Dev. Neurosci. 16:1994;152-161.
7. Brundin L., Svenungsson E., Morcos E., Andersson M., Olsson T., Lundberg I., Wiklund N.P. CNS nitric oxide formation in cerebral SLE. Ann. Neurol. 44:1998;704-706.
8. Brundin L., Morcos E., Olsson T., Wiklund N.P., Andersson M. Increased intrathecal nitric oxide formation in multiple sclerosis; cerebrospinal fluid nitrite as a activity marker. Eur. J. Neurol. 6:1999;585-590.
9. Chao C.C., Hu S., Molitor T.W., Shaskan E.G., Peterson P.K. Activated microglia mediate neuronal cell injury via nitric oxide mechanism. J. Immunol. 149:1992;2731-2736.
10. Cross A.H., Manning P.T., Keeling R.M., Schmidt R.E., Misko T.P. Peroxynitrite formation within the central nervous system in active multiple sclerosis. J. Neuroimmunol. 88:1998;45-56.
11. Dawson V.L., Brahmbatt H.P., Mong J.A., Dawson T.M. Expression of inducible nitric oxide synthase causes delayed neurotoxicity in primary mixed neuronal glial cell cultures. Neuropharmacology. 33:1994;1425-1430.
12. De Bustos F., Navarro J.A., de Andres C., Molina J.A., Jimenez-Jimenez F.J., Orti-Pareja M., Gasalla T., Tallon-Barranco A., Martinez-Salio A., Arenas J. Cerebrospinal fluid nitrate levels in patients with multiple sclerosis. Eur. J. Neurol. 41:1999;44-47.
13. De Groot C.J., Ruuls S.R., Theeuwes J.W., Dijkstra C.D., Van der Valk P. Immunocytochemical characterisation of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 56:1997;10-20.
14. Drulovic J., Dujmovic I., Mesaros S., Samardzic T., Maksimovic D., Stojsalevic N., Levic Z., Stojkovic M.M. Raised cerebrospinal fluid nitrite and nitrate levels in patients with multiple sclerosis: no correlation to disease activity. Mult. Scler. 7:2001;19-22.
15. Ehren I., Hosseini A., Lundberg J.O., Wiklund N.P. Nitric oxide: a useful gas in the detection of lower urinary tract inflammation. J. Urol. 162(2):1999;327-329. (Aug.).
16. Feelisch M., Stamler J.S. Measurements of NO-related activities-which assay for which purpose. Feelisch M., Stamler J. Methods in Nitric Oxide Research. 1996;303-309 Wiley, England.
17. Giovannoni G. Cerebrospinal fluid and serum nitric oxide metabolites in patients with multiple sclerosis. Mult. Scler. 4:1998;27-30.
18. Herulf M., Ljung T., Hellstrom P.M., Weitzberg E., Lundberg J.O.N. Increased luminal nitric oxide in inflammatory bowel disease as shown with a novel minimally invasive method. Scand. J. Gastroenterol. 33(2):1998;164-169. (Feb.).
19. Hofman R.M., Hinton D.R., Johnson K., Merill K.E. Tumor necrosis factor identified in multiple sclerosis brain. J. Exp. Med. 170:1989;607-612.
20. Ignarro L.J., Fukuto J.M., Griscavage J.M., Rogers N.E., Byrns R.E. Oxidation of nitric oxide in an aqueous solution to nitrite but not nitrate: comparison with enzymatically formed nitric oxide from L-arginine. Proc. Natl. Acad. Sci. U. S. A. 90:1993;8103-8107.
21. Ikeda M., Sato I., Matsunaga T., Takahashi M., Yuasa T., Murota S. Cyclic guanosine monophosphate (cGMP), nitrite and nitrate in the cerebrospinal fluid in meningitis, multiple sclerosis and Guillain-Barre syndrome. Intern. Med. 34:1995;734-737.
22. Johnson A.W., Land J.M., Thompson E.J., Bolanos J.P., Clark J.B., Heales S.J.R. Evidence for increased nitric oxide production in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 58:1995;107.
23. Koprowski H., Zheng Y.M., Heber-Katz E., Fraser N., Rorke L., Fu Z.F., Hanlon C., Dietzschold B. In vivo expression of inducible nitric oxide synthase in experimentally induced neurological diseases. Proc. Natl. Acad. Sci. U. S. A. 90:1993;3024-3027.
24. Kornek B., Storch M.K., Weissert R., Wallstroem E., Stefferl A., Olsson T., Linington C., Schmidbauer M., Lassmann H. Multiple sclerosis and chronic autoimmune encephalomyelitis. A comparative quantitative study of axonal injury in active, inactive and remyelinated lesions. Am. J. Pathol. 157:2000;267-276.
25. Kornelisse R.F., Hoeckman K., Visser J.J., Hop W.C.J., Huijmans J.G.M., van der Straaten P.J.C., van der Heijden A.J., Sukhai R.N., Neijdens H.J., de Groot R. The role of nitric oxide in bacterial meningitis in children. J. Infect. Dis. 174:1996;120-126.
26. Kraus J., Engelhardt B., Chatzimanolis N., Bauer R., Tofighi J., Kuehne B.S., Laske C., Stolz E., Frielinghaus P., Schaefer C., Blaes F., Traupe H., Kaps M., Oschmann P. Cell surface bound and adhesion molecules in CSF and blood in multiple sclerosis: correlation with MRI-measures of subclinical disease severity and activity. J. Neuroimmunol. 122(1-2):2002;175-185.
27. Kwon N.S., Stuehr D.J., Nathan C.F. Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide. J. Exp. Med. 174:1991;761-767.
28. Leone A.M., Francis P.L., Rhodes P., Moncada S. A rapid and simple method for the measurement of nitrite and nitrate in plasma by high performance capillary electrophoresis. Biochem. Biophys. Res. Commun. 200(2):1994;951-957.
29. Lipton S.A., Choi Y.-B., Pan Z.H. A redox based mechanism for the neuroprotective and neurodestructive effects of nitric and related nitroso-compounds. Nature. 364:1993;626-632.
30. Lorente J.A., Landin L., Renes E., De Pablo R., Jorge P., Rodena E., Liste D. Role of nitric oxide in the hemodynamic changes of sepsis. Crit. Care Med. 21:1993;759-767.
31. Lublin F., Reingold S. Defining the clinical course of multiple sclerosis: result of an international survey. Neurology. 46:1996;907-911.
32. Lycke J.N., Karlsson J.E., Andersen O., Rosengren L.E. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 64:1998;402-404.
33. Merrill J.E., Ignarro L.J., Sherman M.P., Melinek J., Lane T.E. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J. Immunol. 151:1993;2131-2141.
34. Murphy S., Simmons M.L., Agullo L., Feinstein D.L., Galea E., Reis D.J., Minc-Colomb D., Schwartz J.P. Synthesis of nitric oxide in CNS glial cells. Trends Neurosci. 16:1993;323-328.
35. Nathan C.F., Hibbs J.B. Role of Nitric oxide synthesis in macrophages antimicrobial activity. Curr. Opin. Immunol. 3(1):1991;65-70.
36. O'Brien N.C., Charlton B., Cowden W.B., Willenborg D.O. Inhibition of nitric oxide synthase initiates relapsing remitting experimental autoimmune encephalomyelitis in rats, yet nitric oxide appears to be essential for clinical expression of disease. J. Immunol. 167:2001;5904-5912.
37. Olsson T. Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol. Rev. 144:1995;245-268.
38. Palmer R.M.J., Ferrige A.G., Moncada S. Nitric oxide release account for the biological activity of endothelium-derived relaxing factor. Nature. 327:1987;524-526.
39. Paolio A., Coles A.J., Molineux M.R.C.P., Gawne-Cain M., MacManus D., Barker G.J., Compston D.A.S., Miller D.H.et al. Quantitative MRI in Patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology. 53:1999;751-757.
40. Peltola J., Ukkonen M., Moilanen E., Elovaara Il. Increased nitric oxide products in CSF in primary progressive MS may reflect brain atrophy. Neurology. 57:2001;895-896.
41. Poser C.M., Paty D.W., Scheinberg L., Mc Donald W.I., Davis F.A., Ebers C.G., Johnson K.P., Sibley W.A., Silberberg D.H., Toureltotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13:1983;227-231.
42. Redford E.J., Kapoor R., Smith K.J. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain. 120:1997;2149-2157.
43. 2+-independent nitric oxide synthases. FEBS Lett. 291:1991;145-149.
44. Selmaj K., Raine C.S., Cannella B., Brosnan C.F. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J. Clin. Invest. 87:1991;949-958.
45. Smith K.J., Kapoor R., Hall S.M., Davies M. Electrically active axons degenerate when exposed to nitric oxide. Ann. Neurol. 49:2001;470-476.
46. Steinman L. Multiple sclerosis: a two-stage disease. Nat. Immunol. 2:2001;762-775
47. Subclinical disease severity and activity. J. Neuroimmunol. 122:2001;175-185.
48. Svenningsson A., Petersson A.S., Andersen O., Hansson G.K. Nitric oxide metabolites in CSF of patients with MS are related to clinical disease course. Neurology. 53:1999;1880-1882.
49. Taskiran D., Sagduyu A., Yuceyar N., Kutay F.Z., Pogun S. Increased cerebrospinal fluid and serum nitrite and nitrate levels in amyotrophic lateral sclerosis. Int. J. Neurosci. 101(1-4):2000;65-72.
50. Trapp B.D., Ransohoff R., Rudic R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr. Opin. Neurol. 3:1999;295-302.
51. Visser J.J., Scholten R.J.P.M., Hoekman K. Nitric oxide synthesis in bacterial meningitis. Ann. Intern. Med. 120:1994;345-346.
52. Wink D.A., Kasprzak K.S., Maragos C.M., Elesperu R.K., Misra M., Dunams T.M., Cebula T.A., Koch W.H., Andrews A.W., Allen J.S. DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science. 254:1991;1001-1003.
53. -) levels in patients with multiple sclerosis. J. Neurol. Sci. 153:1997;32-34.
54. Yuceyar N., Taskiran D., Sagduyu A. Serum and cerebrospinal fluid nitrite and nitrate levels in relapsing remitting and secondary progressive multiple sclerosis patients. Clin. Neurol. Neurosurg. 103:2001;206-2011.